Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
1 hedge funds and large institutions have $7.13K invested in Galera Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 35 closing their positions.
97% less funds holding
Funds holding: 36 → 1 (-35)
99% less capital invested
Capital invested by funds: $1.37M → $7.13K (-$1.36M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$4.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$509K |
| 2 |
Blackstone Inc
New York
|
-$235K |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$126K |
| 4 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$85.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$62.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
26
Two Sigma Securities
New York
| – | -$1.7K | -12,143 | Closed |
|
|
JWCA
27
J.W. Cole Advisors
Tampa,
Florida
| – | -$1.68K | -12,000 | Closed |
|
|
PA
28
Parallel Advisors
San Francisco,
California
| – | -$1.1K | -7,867 | Closed |
|
|
N
29
Natixis
Paris,
France
| – | -$774 | -5,000 | Closed |
|
30
US Bancorp
Minneapolis,
Minnesota
| – | -$420 | -3,000 | Closed |
|
31
Morgan Stanley
New York
| – | -$396 | -2,831 | Closed |
|
32
Wells Fargo
San Francisco,
California
| – | -$195 | -1,391 | Closed |
|
|
LF
33
LifeSteps Financial
Claremont,
California
| – | -$122 | -870 | Closed |
|
34
Fidelity Investments
Boston,
Massachusetts
| – | -$106 | -757 | Closed |
|
35
JP Morgan Chase
New York
| – | -$3 | -24 | Closed |
|
GRTX Hedge Fund Activity: Q2 2024 in Review
1 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q2 2024, worth a combined $7.13K — down 99% from $1.37M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of GRTX and 0 opened new positions — a net loss of 35 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was XTX Topco, adding an estimated $4.86K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $509K sold.
- 1 institutional investor held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q2 2024, down from 36 in Q1 2024.
- Funds reported $7.13K of Galera Therapeutics, Inc. Common Stock stock for Q2 2024, down 99% quarter-over-quarter.
- 0 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q2 2024 and 35 closed out, a net change of -35 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q2 2024 was XTX Topco, an estimated $4.86K added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q2 2024 was GSA Capital Partners, an estimated $509K sold.
Based on aggregated 13F filings for Q2 2024.